Enrich Bioscience has built, is now validating and will soon market an accurate and affordable molecular blood test-kit for early cancer detection.  
Current cancer detection methods can capture only one cancer at a time.  Cancer, when detected early, has more therapeutic options and results in higher survival rates. However, with no symptoms, it is difficult to screen for cancer. 
Enrich Bioscience has met this need and has build, is currently validating and will soon market a single, accurate and affordable molecular blood test-kit that can screen any cancer type before symptoms appear.  Our simple test is
• A single liquid biopsy test comprised of 1000 plus of DNA-biomarkers is capable of detecting many cancers.
• 100 times more sensitive than current testing methods.
• 70% less expensive than the current cancer diagnostic test.
A disruptive and scalable technology 
Disruptive Technology- Enrich BioScience’s test affordability and accessibility will create new markets.
Scalability- Enrich Bioscience’s testing model can be applied to other diseases.
The market size for Enrich Bioscience’s test 
Global market in 2017 was valued at 3.85 billion USD and is projected to grow to 21.6 billion USD by 2026.  

Enrich Bioscience is currently in a very unique and exciting position within the Bio Medical industry. 

Biotechnology

Health Care

Enrich Bioscience

Enrich Bioscience's headquarters in Toronto, Canada

Sun Chong Wang

Enrich Bioscience

Org chart

Board & advisors

Teams

Offices

Similar companies